Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 2 clinical study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies. The study aims to determine the safety and effectiveness of ABBV-932 when added to existing antidepressant treatments for adults with generalized anxiety disorder (GAD) who have not responded adequately to antidepressants alone.
The intervention being tested is ABBV-932, an investigational oral drug designed to be used alongside standard antidepressant therapies (ADT) for treating GAD. Participants will receive either ABBV-932 or a placebo in addition to their current ADT regimen.
This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. Its primary purpose is to assess treatment efficacy and safety.
The study began on April 29, 2025, with recruitment currently ongoing. The last update was submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
The outcome of this study could significantly impact AbbVie’s stock performance and investor sentiment, especially if ABBV-932 proves effective. This could position AbbVie favorably against competitors in the anxiety disorder treatment market, potentially leading to increased market share.
The study is ongoing, with further details available on the ClinicalTrials portal.